For Healthcare Professionals

A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)

clipboard-pencil

About the study

The purpose of this neoadjuvant study is to compare nivolumab plus chemotherapy and chemotherapy alone in terms of safety and effectiveness, and to describe nivolumab plus ipilimumab's safety and effectiveness in treating resectable NSCLC. This study has multiple primary endpoints.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:


  1. Early stage IB-IIIA, operable non-small cell lung cancer, confirmed in tissue
  2. Lung function capacity capable of tolerating the proposed lung surgery
  3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1
  4. Available tissue of primary lung tumor

EXCLUSION CRITERIA

Exclusion Criteria:


  1. Presence of locally advanced, inoperable or metastatic disease
  2. Participants with active, known or suspected autoimmune disease
  3. Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors)

Other protocol defined inclusion/exclusion criteria apply


pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.

Study’s details


Contition

Non Small Cell Lung Cancer

Age (in years)

18+

Phase

Phase 3

Participants needed

505

Est. Completion Date

Nov 8, 2028

Treatment type

Interventional


Sponsor

Bristol-Myers Squibb

ClinicalTrials.gov identifier

NCT02998528

Study number

CA209816

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.